2020 ttf alk qa panel ros1 clinical trial updates
Published 3 years ago • 16 plays • Length 3:24Download video MP4
Download video MP3
Similar videos
-
2:16
2020 ttf alk session qa panel ros1 patients on immunotherapy chemotherapy combinations
-
4:08
2020 ttf alk/ros session qa panel treatment decisions for simultaneous egfr and ros1 mutation
-
1:50
2020 ttf alk/ros session qa panel the difference in efficacy of tkis in different patients
-
3:06
2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
-
2:28
2020 ttf alk session qa panel the future of mek inhibitors
-
1:20
2020 ttf alk/ros session qa panel ros1 patient on crizotinib, brain metastases treated with srt
-
4:18
2020 ttf rare mutations qa panel qualifying for a clinical trial
-
1:57
video 2020 ttf alk/ros session qa panel ros1 patients - chemo after resistance to inhibitor therapy?
-
4:20
video 2020 ttf alk/ros session qa panel the efficacy of dose reduction or interruption of crizotinib
-
3:46
2020 ttf alk session qa panel the use of an alk tki post chemoradiation for stage 3b lung cancer
-
25:07
2020 ttf alk session - lin - tkis for ros1
-
2:16
2020 ttf alk session qa panel using ctc profiling to detect crizotinib resistance on progression
-
6:56
2020 ttf rare mutations qa panel why mutations have different progression-free survival averages
-
1:43
2020 ttf alk session qa panel reducing dosage on lorlatinib vs switching to a different agent
-
2:34
2020 ttf alk session qa panel next steps after progression on lorlatinib
-
2:36
2020 ttf alk session qa panel information on the crown trial and firstline lorlatinib
-
4:20
2020 ttf rare mutations qa panel - the importance of broad molecular testing
-
2:06
2020 ttf egfr qa panel updates combo treatment of osimertinib (tagrisso) & ramucirumab (cyramza)